Literature DB >> 2913475

Enhanced cis-platinum ototoxicity in children with brain tumours who have received simultaneous or prior cranial irradiation.

D A Walker1, J Pillow, K D Waters, E Keir.   

Abstract

We report on four children who received cis-platinum simultaneously with, or in one case 10 months after, cranial irradiation and experienced exaggerated ototoxicity affecting all audible frequencies. The hearing loss was severe, affecting the critical areas for speech perception, and necessitated the provision of bilateral hearing aids. The audiograms of these patients are shown and compared to those of four children who had received cis-platinum as part of their treatment for neuroblastoma but without cranial irradiation. The precipitation of the exaggerated hearing loss with the administration of cis-platinum in one patient 10 months after finishing cranial irradiation suggests that care should be taken in the timing of cis-platinum administration in relation to concurrent or previous cranial irradiation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2913475     DOI: 10.1002/mpo.2950170110

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  18 in total

Review 1.  Evaluation and Management of Hearing Loss in Survivors of Childhood and Adolescent Cancers: A Report From the Children's Oncology Group.

Authors:  Johnnie K Bass; Kristin R Knight; Torunn I Yock; Kay W Chang; Douglas Cipkala; Satkiran S Grewal
Journal:  Pediatr Blood Cancer       Date:  2016-02-29       Impact factor: 3.167

2.  Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: report from the Children's Oncology Group.

Authors:  Amulya A Nageswara Rao; Dana J Wallace; Catherine Billups; James M Boyett; Amar Gajjar; Roger J Packer
Journal:  Pediatr Blood Cancer       Date:  2013-08-19       Impact factor: 3.167

Review 3.  Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale.

Authors:  Penelope R Brock; Kristin R Knight; David R Freyer; Kathleen C M Campbell; Peter S Steyger; Brian W Blakley; Shahrad R Rassekh; Kay W Chang; Brian J Fligor; Kaukab Rajput; Michael Sullivan; Edward A Neuwelt
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

Review 4.  Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group.

Authors:  Satkiran Grewal; Thomas Merchant; Renee Reymond; Maryrose McInerney; Cathy Hodge; Patricia Shearer
Journal:  Pediatrics       Date:  2010-03-01       Impact factor: 7.124

5.  Auditory complications in childhood cancer survivors: a report from the childhood cancer survivor study.

Authors:  Kimberly Whelan; Kayla Stratton; Toana Kawashima; Wendy Leisenring; Susan Hayashi; John Waterbor; Julie Blatt; Charles A Sklar; Roger Packer; Pauline Mitby; Leslie L Robison; Ann C Mertens
Journal:  Pediatr Blood Cancer       Date:  2011-02-15       Impact factor: 3.167

6.  Cisplatin and cranial irradiation-related hearing loss in children.

Authors:  Rajasekharan Warrier; Aman Chauhan; Murali Davluri; Sonya L Tedesco; Joseph Nadell; Randall Craver
Journal:  Ochsner J       Date:  2012

7.  Platinum-based chemotherapy for recurrent CNS tumours in young patients.

Authors:  E Douek; J E Kingston; J S Malpas; P N Plowman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-08       Impact factor: 10.154

Review 8.  TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.

Authors:  Daniel B Hawcutt; Munir Pirmohamed; Signe Thiesen; Peng Yin; Andrea L Jorgensen; Jieying Eunice Zhang; Valentina Manzo; Laurence McEvoy; Christopher Barton; Susan Picton; Simon Bailey; Penelope Brock; Harish Vyas; David Walker; Guy Makin; Srinivas Bandi; Barry Pizer
Journal:  Pharmacogenet Genomics       Date:  2017-06       Impact factor: 2.089

Review 9.  Core deficits and quality of survival after childhood medulloblastoma: a review.

Authors:  Mathilde Chevignard; Hugo Câmara-Costa; François Doz; Georges Dellatolas
Journal:  Neurooncol Pract       Date:  2016-08-26

10.  Quality of survival and cognitive performance in children treated for medulloblastoma in the PNET 4 randomized controlled trial.

Authors:  Hugo Câmara-Costa; Kim S Bull; Colin Kennedy; Andreas Wiener; Gabriele Calaminus; Anika Resch; Virginie Kieffer; Clémence Lalande; Geraldina Poggi; Katja von Hoff; Jacques Grill; François Doz; Stefan Rutkowski; Maura Massimino; Rolf-Dieter Kortmann; Birgitta Lannering; Georges Dellatolas; Mathilde Chevignard
Journal:  Neurooncol Pract       Date:  2017-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.